TUESDAY, SEPTEMBER 19, 2017

Paragon Bioservices gains contract for HIV vaccine candidate

Paragon Bioservices, a biopharmaceuticals and vaccines manufacturer, recently gained a contract from the International AIDS Vaccine Initiative (IAVI) to create an HIV vaccine candidate. Read More »

NIH encourages acceleration to eliminate AIDS

The National Institutes of Health (NIH) recently released statements in honor of World AIDS Day that encourage scientists to speed their efforts to eliminate AIDS as soon as possible. Read More »

NIAID researchers create blueprint for HIV prevention and treatment

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), have used evidence from three large clinical trials to develop a blueprint of prevention and treatment for HIV infections. Read More »

Research standards for HOPE Act released

The Department of Health and Human Services (HHS) recently published the research safeguards and criteria that are part of the HIV Organ Policy Equity (HOPE) Act. Read More »

Scientists find relations in liver cells and malaria parasites

Center for Infectious Disease Research scientists have discovered an important link in the interactions involving malaria parasites and liver cells in the host. Read More »

New partnership to create vaccine for dengue virus

The U.S. Army Medical Research and Materiel Command (USAMRMC) and Upstate Medical University in New York have partnered to create a vaccine that will protect people from dengue fever. Read More »

NIH issues criteria for HIV-positive organ transplant research

The National Institutes of Health (NIH) issued criteria last week on research on possible organ transplants between HIV-positive patients. Read More »

Phase 2 clinical trial of chikungunya vaccine opens to volunteers

A vaccine clinical trial to combat the mosquito-borne chikungunya virus is being sponsored by National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID). Read More »

FDA approves flu drug for those 65 and older

Fluad, a seasonal flu drug that contains an adjuvant, has gained first-of-its-kind market approval from the Food and Drug Administration to be used by people who are over 65. Read More »

National Institutes for Health recommends ways to avoid Type 2 diabetes

Health professionals recently recommended a variety of ways to avoid developing Type 2 diabetes by losing weight in new, creative ways. Read More »

Cambridge TB study uses zebrafish as pathogenesis model

A researcher from Cambridge University has found that zebrafish serve as a suitable model for tuberculosis (TB) pathogenesis studies. Read More »

NIH introduces improved tools for HIV treatment

The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), recently began an initiative to further develop long-lasting treatments and prevention for HIV infections. Read More »

University of Maryland's Ebola vaccine declared safe and effective

A recent clinical trial shows that a new Ebola vaccine (ChAd3-EBO-Z) provokes a strong immune response and has positive toleration in adults living in Mali and in the U.S. Read More »

Profectus shares preclinical data for vaccine against Ebola and Marburg

Profectus Biosciences Inc., a clinical-stage vaccine company that creates vaccines to prevent and treat cancer and infectious diseases, recently gave a presentation of pre-clinical data for a multi-component vaccine that is designed to protect people from the Zaire and Sudan strains of Ebola and Marburg viruses. Read More »

South Florida team develops new model for antimalarial drug screening

The University of South Florida (USF) Center for Global Health & Infectious Diseases Research recently developed a novel model for screening antimalarial drugs. Read More »

Ebola drug has success on human patient

A drug developed to combat Ebola has been phased for a clinical trial on healthy, human volunteers. Read More »

Gorilla adenovectors emphasized at Vaccines R&D conference

A representative of GenVec Inc., a clinical-stage gene delivery company -- recently made a presentation emphasizing the importance of gorilla adenovectors at the Vaccines R&D 2015 Conference. Read More »

Anti-HIV drug effective for pregnant women with nevirapine exposure

A recent study suggests that efiavirenz, an anti-HIV drug, both safely and effectively inhibits the transmission of HIV from mothers to children when nevirapine exposure is provided in the womb. Read More »

HHS announces openings for HIV-1 and AIDS vaccine development applications

The Department of Health and Human Services (HHS) recently made a Funding Opportunity Announcement (FOA) for its acceptance of applications to develop the B cells of an HIV-1 vaccine. Read More »

Saint Louis University receives NIH contract for omics research

The Vaccine and Treatment Evaluation Unit of Saint Louis University recently gained a contract with the National Institutes of Health for the scientists’ “omics” research initiative, which studies the efficacy and safety of vaccines and similar methods of fighting infectious diseases. Read More »